Literature DB >> 16924360

Management and outcome of intravenous gammaglobulin-resistant Kawasaki disease.

R Sittiwangkul1, Y Pongprot, S Silvilairat, C Phornphutkul.   

Abstract

INTRODUCTION: This study aimed to determine the prevalence and risk of intravenous gammaglobulin (IVIG)-resistant Kawasaki disease (KD) and report the outcome of treatment in patients with persistent or recurrent fever.
METHODS: 70 KD patients, who received IVIG treatment (2 g/kg) at a tertiary care hospital from January 1995 to June 2004, were retrospectively reviewed.
RESULTS: Nine (13 percent) of the 70 patients failed to respond to initial treatment with IVIG. The patients who did not respond to IVIG had higher erythrocyte sedimentation rate (ESR) (104 versus 74 mm/h; p-value is 0.003), longer total days of fever (14.4 +/- 3.8 versus 9.2 +/- 2.3 days; p-value is 0.003) and higher initial coronary artery lesions (CAL) (7 of 9 [77.7 percent] versus 10 of 61 [16.3 percent]; p-value is 0.001) than those who responded to initial treatment. Seven of the nine patients who were retreated with IVIG (2 g/kg) responded to the second dose. The remaining two patients (two of nine, 22 percent) had persistent fever, which subsided after two to three doses of pulse intravenous methylprednisolone. At two months follow-up, IVIG-resistant patients had higher CAL by echocardiogram than IVIG-responsive patients (33 percent versus 3.2 percent, p-value is less than 0.05). Two IVIG-resistant KD patients had delayed diagnosis and developed giant aneurysms.
CONCLUSION: Patients with high ESR had increased risk of IVIG-resistant KD. IVIG-resistant Kawasaki patients had a higher prevalence of CAL at the acute phase and two months after onset.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16924360

Source DB:  PubMed          Journal:  Singapore Med J        ISSN: 0037-5675            Impact factor:   1.858


  10 in total

1.  Abnormal liver panel in acute kawasaki disease.

Authors:  Mohammed Eladawy; Samuel R Dominguez; Marsha S Anderson; Mary P Glodé
Journal:  Pediatr Infect Dis J       Date:  2011-02       Impact factor: 2.129

Review 2.  Use of corticosteroids during acute phase of Kawasaki disease.

Authors:  Jeong Jin Yu
Journal:  World J Clin Pediatr       Date:  2015-11-08

3.  Immunoglobulin Resistance in Kawasaki Disease.

Authors:  Georgios A Hartas; Syed Shahrukh Hashmi; Chi Pham-Peyton; Emmanouil Tsounias; John T Bricker; Monesha Gupta-Malhotra
Journal:  Pediatr Allergy Immunol Pulmonol       Date:  2015-03-01       Impact factor: 1.349

4.  Association of CCR2-CCR5 haplotypes and CCL3L1 copy number with Kawasaki Disease, coronary artery lesions, and IVIG responses in Japanese children.

Authors:  Manju Mamtani; Tomoyo Matsubara; Chisato Shimizu; Susumu Furukawa; Teiji Akagi; Yoshihiro Onouchi; Akira Hata; Akihiro Fujino; Weijing He; Sunil K Ahuja; Jane C Burns
Journal:  PLoS One       Date:  2010-07-07       Impact factor: 3.240

5.  Epidemiology of immunoglobulin resistant Kawasaki disease: results from a large, national database.

Authors:  Brady S Moffett; Dorothy Syblik; Susan Denfield; Carolyn Altman; Kristin Tejtel-Sexson
Journal:  Pediatr Cardiol       Date:  2014-09-02       Impact factor: 1.655

6.  Resistance to intravenous immunoglobulin in children with Kawasaki disease.

Authors:  Adriana H Tremoulet; Brookie M Best; Sungchan Song; Susan Wang; Elena Corinaldesi; Julia R Eichenfield; Danielle D Martin; Jane W Newburger; Jane C Burns
Journal:  J Pediatr       Date:  2008-03-04       Impact factor: 4.406

7.  Identification of SAMD9L as a susceptibility locus for intravenous immunoglobulin resistance in Kawasaki disease by genome-wide association analysis.

Authors:  Jae-Jung Kim; Sin Weon Yun; Jeong Jin Yu; Kyung Lim Yoon; Kyung-Yil Lee; Hong-Ryang Kil; Gi Beom Kim; Myung-Ki Han; Min Seob Song; Hyoung Doo Lee; Kee Soo Ha; Sejung Sohn; Ryota Ebata; Hiromichi Hamada; Hiroyuki Suzuki; Kaoru Ito; Yoshihiro Onouchi; Young Mi Hong; Gi Young Jang; Jong-Keuk Lee
Journal:  Pharmacogenomics J       Date:  2019-04-11       Impact factor: 3.550

8.  Prediction of unresponsiveness to second intravenous immunoglobulin treatment in patients with Kawasaki disease refractory to initial treatment.

Authors:  Euri Seo; Jeong Jin Yu; Hyun Ok Jun; Eun Jung Shin; Jae Suk Baek; Young-Hwue Kim; Jae-Kon Ko
Journal:  Korean J Pediatr       Date:  2016-10-17

Review 9.  Kawasaki Disease: The Role of Immune Complexes Revisited.

Authors:  Stephanie Menikou; Paul R Langford; Michael Levin
Journal:  Front Immunol       Date:  2019-06-12       Impact factor: 7.561

10.  Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?-Current evidence based on a meta-analysis.

Authors:  Xiaolan Zheng; Jinhui Li; Peng Yue; Lei Liu; Jiawen Li; Kaiyu Zhou; Yimin Hua; Yifei Li
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.